🕒 Last update: loading…21/11/2026

Stock Autonomix Medical, Inc. AMIX

Autonomix Medical, Inc. — Investlytic score 1/5 on the five criteria.

-
-
20/ 100
Score Investlytic · 5 criteria

Analysis in progress…

Investlytic score: 1/5 criteria met. Data as of 01/11/2026.

  • ❌ Price trend failed
  • ❌ Growth failed
  • ✅ Debt passed
  • ❌ P/E failed
  • ❌ Correction failed

Price trend

Overall trend (8 years): insufficient progression (less than x1.5).

Price change 2024 → 2025: -85.37%

Price change 2025 → 2026: -84.33%

Price change 2026 (year to date): -83.95%

Financial growth

Revenue CAGR (5 years): N/A

Earnings CAGR (5 years): N/A

Growth status: insufficient data or negative trend.

Debt

Debt-to-equity ratio: 0.00

Debt/equity < 0.5 (maximum threshold).

P/E (Price/Earnings)

P/E ratio: -0.04

P/E > 25.0 (maximum threshold).

Correction (6 months)

Current correction: 90.72% from the high over 6 months.

Excessive correction (> 20.0%).

WATCH
The stock is currently being evaluated.

Criteria of the Investlytic model

- / 5
🔒

Investlytic rating reserved for members

Score out of 100, model verdict (buy, watch, sell) and details of the 5 criteria · visible with a free account.

02

Price trend

Price & trend

Interactive chart →
Loading chart…

⚖️ Comparison with the market

All stocks →
StockP/EDette/FPRevenue growthRating
Autonomix Medical, Inc. Common Stock–0.00–🔒
WORK Medical Technology Group Ltd.–0.35−28.4 %–
Spineway S.A.–0.07+9.3 %–
CompuMed, Inc.–0.23+10.2 %–
SpineGuard S.A.–0.27+1.6 %–

Data from the Investlytic screener. The rating of the stock being viewed is reserved for members.

03

Detailed analysis · Price trend

-

🔒

Reserved for members

Global model trend and annual price variations · visible with a free account.

04

Revenues & profits

Revenue and net income

🔒

Reserved for members

Chart of revenues and net income over 8 periods · real data, no estimates.

05

Financial indicators

🔒

Reserved for members

18 financial indicators analyzed by groups of criteria: valuation, profitability, growth, solidity, dividend, and momentum.

06

Annual financial statements

Fiscal yearRevenueNet income Net marginEPSRevenue growth
🔒

Reserved for members

Complete annual financial statements: revenue, net income, margin, and EPS over 8 fiscal years.

+

Accounts and financial health

Balance sheet and cash flow published by Autonomix Medical, Inc. over the last fiscal years, strength scores and valuation by discounted cash flow (DCF).

Overview
fragile accounts
according to Altman Z, Piotroski and net debt
Altman Z-score
-15.95
risk zone (below 1.81)
Piotroski Score
1 / 9
0 to 3: fragile accounts
Net Debt / EBITDA
0.65 x
low debt
Fiscal year20222023202420252026
Cash and investments2.0 m865,0008.6 m9.1 m7.0 m
Total Debt001.0 m00
Net Debt-2.0 m-865,000-7.6 m-9.1 m-7.0 m
Equity2.0 m644,0007.6 m8.1 m5.9 m
Total assets2.1 m865,0009.4 m9.8 m7.6 m
Operating cash flow-387,307-1.9 m-6.6 m-8.3 m-12.3 m
Investments (capex)3019,00014,00010,000
Free cash-flow-387,310-1.9 m-6.7 m-8.3 m-12.3 m
Share buybacks00000
Dividends paid00000

Amounts in USD, currency of the published accounts.

Trailing 12-month ratios

Price / earnings (P/E)-0.05 x
Price / book value0.19 x
Return on Equity (ROE)-191.9 %
Return on Invested Capital (ROIC)-173.3 %
Net margin0.0 %
Debt / equity0.00 x
Current ratio6.52 x
Free cash-flow yield-2,130.0 %

Altman Z: default risk estimated from the balance sheet and earnings. Piotroski: 9 tests on profitability, debt and efficiency. DCF: estimated value from discounted future cash flows, a model and not a forecast. Source: annual accounts published by the company, data as of 20/11/2026.

+

Dividends and earnings

Autonomix Medical, Inc.: dividend history, last distributions, stock splits and earnings releases.

No known dividend for this company.

Earnings releases

DatePublished EPSExpected EPSSurprise
10/11/2026-2.51-2.62n/a
12/08/2026-5.02-6.40n/a
04/06/2026-4.83-4.83n/a
12/02/2026-7.56-7.56n/a
14/11/2025-28.98-31.50n/a
13/08/2025-22.47-18.59n/a

Stock splits

DateOperation
24/06/2026reverse split: 1 share for 21

Factual data: ex-dividend history and earnings calendar, as of 20/11/2026. A past dividend does not guarantee the next one.

+

PEA and practical information

PEA eligibility
no
head office outside the EU and EEA
Listing exchange
Nasdaq
IPO: 29/01/2024
ISIN code
US05330T2050
Workforce
5
full-time employees
Chief executive
Bradley Hauser

Rule applied: the French PEA accepts shares of companies headquartered in the European Union or the European Economic Area and subject to corporate income tax; ADRs and tax-exempt property companies (SIIC) are excluded. The institution holding the PEA confirms eligibility.

?

Frequently asked questions about Autonomix Medical, Inc.

What is the Autonomix Medical, Inc. share price?

Latest recorded price: 1.37 USD on 13/11/2026, for a market cap of 744,324 USD.

Is Autonomix Medical, Inc. stock eligible for the French PEA?

No: the company is headquartered outside the European Union and the European Economic Area (ISIN US05330T2050).

How many employees does Autonomix Medical, Inc. have?

5 full-time employees according to the latest published profile.

Who runs Autonomix Medical, Inc.?

Bradley Hauser is the company's chief executive.

07

Similar stocks